Global Life Science Ventures — Investing in the life sciences

Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund may also invest in selected later stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds totalling more than € 200 million. With offices in Germany and Switzerland, GLSV acts as one team with a global perspective.

Profile
Team
Investment Practice
Portfolio
FAQ
Download Area
News
Events
Contact Us
Text size

GLSV news

30.01.2012 Global Life Science Ventures: 2011 Review more...

24.01.2011 Global Life Science Ventures: 2010 Review more...

14.01.2010 Global Life Science Ventures: 2009 Review more...

13.02.2009 Global Life Science Ventures: 2008 highlights more...

22.04.2008 GLSV receives 2007 Dyodelta European Life Science Innovation Award "Investor of the Year Award" more...

More News


Portfolio company news

03.05.2012 Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury more...

25.04.2012 Henrik Stage Appointed Interim CEO of Santaris Pharma A/S more...

19.04.2012 Santaris Pharma A/S presents final Phase 2a study results for miravirsen showing dose-dependent, prolonged antiviral activity in Hepatitis C patients more...

05.04.2012 Zalicus Discovers Novel Multi-Target Mechanism for the Treatment of Multiple Myeloma more...

04.04.2012 Pieris Presents Preclinical Data for PRS-110 c-Met Antagonist Anticalin at the AACR Annual Meeting more...

More News